# US 2004/0082587 A1 · 2,4,6-Triaminopyrimidines for the treatment of depression and/or anxiety

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2004/0082587 A1
- Document ID: US20040082587A1
- Status: Published application
- Kind: A1
- Application number: 10/638,602
- Filed: 2003-08-07
- Published: 2004-04-29
- Earliest claimed: 2002-08-07
- Assignees: H. Lunobeck A/S
- Inventors: Mathivanan Packiarajan
- Web page: https://patentgrep.com/patent/US20040082587A1

## CPC

- C07D 239/50: Three nitrogen atoms
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)

## Abstract

This invention is directed to pyrimidine derivatives which are selective antagonists for the GalR3 receptor. The invention provides a pharmaceutical composition comprising a therapeutically effective amount of a compound of the invention and a pharmaceutically acceptable carrier. This invention also provides a pharmaceutical composition made by combining a therapeutically effective amount of a compound of the invention and a pharmaceutically acceptable carrier. This invention further provides a process for making a pharmaceutical composition comprising combining a therapeutically effective amount of a compound of the invention and a pharmaceutically acceptable carrier. This invention also provides a method of treating a subject suffering from depression and/or anxiety which comprises administering to the subject an amount of a compound of the invention effective to treat the subject's depression and/or anxiety. This invention also provides a method of treating depression and/or anxiety in a subject which comprises administering to the subject a composition comprising a pharmaceutically acceptable carrier and a therapeutically effective amount of a GalR3 receptor antagonist.

## Claims

### Claim 1

A compound having the structure:
75

### Claim 2

A compound having the structure:
76

### Claim 3

A compound having the structure:
77

### Claim 4

A compound having the structure:
78

### Claim 5

A compound having the structure:
79

### Claim 6

A compound having the structure:
80
wherein the methyl groups off the morpholine are trans to each other.

### Claim 7 (depends on 6)

The compound of claims 6, wherein the compound is enantiomerically pure.

### Claim 8 (depends on 1, 2, 3, 4, 5, 6)

A pharmaceutical composition comprising a therapeutically effective amount of the compound of any of claims 1 to 6 and a pharmaceutically acceptable carrier.

### Claim 9 (depends on 8)

The pharmaceutical composition of claim 8, wherein the amount of the compound is from about 0.01 mg to about 1000 mg.

### Claim 10 (depends on 9)

The pharmaceutical composition of claim 9, wherein the amount of the compound is from about 0.1 mg to about 500 mg.

### Claim 11 (depends on 10)

The pharmaceutical composition of claim 10, wherein the amount of the compound is from about 1 mg to about 200 mg.

### Claim 12 (depends on 11)

The pharmaceutical composition of claim 11, wherein the amount of the compound is from about 10 mg to about 100 mg.

### Claim 13 (depends on 12)

The pharmaceutical composition of claim 12, wherein the carrier is a liquid and the composition is a solution.

### Claim 14 (depends on 8)

The pharmaceutical composition of claim 8, wherein the carrier is a solid and the composition is a tablet.

### Claim 15 (depends on 8)

The pharmaceutical composition of claim 8, wherein the carrier is a gel and the composition is a suppository.

### Claim 16 (depends on 1, 2, 3, 4, 5, 6, 7)

A process of making a pharmaceutical composition comprising admixing a therapeutically effective amount of the compound of any of claims 1 to 7 and a pharmaceutically acceptable carrier.

### Claim 17 (depends on 1, 2, 3, 4, 5, 6, 7)

A method of treating a subject suffering from depression, which comprises administering to the subject a dose of the compound of any of claims 1 to 7 effective to treat the subject's depression.

### Claim 18 (depends on 1, 2, 3, 4, 5, 6, 7)

A method of treating a subject suffering from anxiety, which comprises administering to the subject a dose of the compound of any of claims 1 to 7 effective to treat the subject's anxiety.

### Claim 19 (depends on 1, 2, 3, 4, 5, 6, 7)

A method of alleviating the symptoms of a disorder in a subject, which comprises administering to the subject a dose of a GalR3 antagonist effective to alleviate the symptoms, wherein the GalR3 antagonist is the compound of any of claims 1 to 7.

### Claim 20 (depends on 17, 18, 19)

The method of any of claims 17 to 19, wherein the therapeutically effective amount is between about 0.01 and about 1000 mg per day.

### Claim 21 (depends on 20)

The method of claim 20, wherein the therapeutically effective amount is between about 0.10 and about 500 mg per day.

### Claim 22 (depends on 21)

The method of claim 21, wherein the therapeutically effective amount is between about 1.0 and about 200 mg per day.

### Claim 23 (depends on 22)

The method of claim 22, wherein the therapeutically effective amount is between about 10 and about 100 mg per day.

### Claim 24 (depends on 17, 18, 19, 20, 21, 22, 23)

The method of any of claims 17 to 23, wherein the compound can be administered orally.

### Claim 25 (depends on 17, 18, 19, 20, 21, 22, 23, 24)

The method of any of claims 17 to 24, wherein the subject is a vertebrate, a mammal, a canine or a human.

### Claim 26 (depends on 17, 18, 19, 20, 21, 22, 23, 24, 25)

The method of any of claims 17 to 25, wherein the compound is administered in combination with food.
